Skip to search formSkip to main contentSkip to account menu

nintedanib

Known as: Intedanib, Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate, methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate 
An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsIndoles

Narrower (3)

BIBF 1120Multitargeted Tyrosine Kinase Inhibitor BIBF 1120vargatef
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
PurposeBoth nintedanib/docetaxel and anti‐PD‐1/PD‐L1 immunotherapies have demonstrated efficacy as second‐line treatment of… 
2019
2019
Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative.
2018
2018
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
Introduction The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary… 
2017
2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
BackgroundNintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer… 
Review
2015
Review
2015
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
2015
2015
S108 Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials
Introduction The two replicate, randomised, placebo-controlled, 52-week Phase III INPULSIS® trials assessed the efficacy and… 
Review
2015
Review
2015
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
Non-small lung cancer (NSCLC) is a lethal malignancy when diagnosed in advanced stage. The evolution of chemotherapy and the… 
2014
2014
Treatments for idiopathic pulmonary fibrosis.
2014
2014
Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials
Background: The INPULSIS™ trials were two replicaterandomized, placebo-controlled, 52-week Phase III trials that assessed the… 
Review
2012
Review
2012
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)